Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions

Kim, Yee Jung; Granstein, Richard D.

doi:10.1016/j.bbih.2021.100361

Cited by 33 publications

(36 citation statements)

References 241 publications

(291 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A regulatory function of CGRP in the skin is known [ 19 ], and a case of severe wound healing disorder has also been described. It is suggested that impaired healing is caused by the inhibition of CGRP and consequently the absent downregulating effects of CGRP on the endothelial proinflammatory cytokines [ 8 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

et al. 2022

View full text Add to dashboard Cite

Background Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerability. However, little is known about possible predictors, dose dependence and time course of development of adverse events (AEs) during the treatment under real-world conditions. Methods Clinical routine data of 128 patients with migraine treated in the West German Headache Center Essen were analyzed regarding AEs during a treatment interval of up to 12 months (3mo n = 128, 6mo n = 105, 9mo n = 74, 12mo n = 54). Patients obtained subcutaneous erenumab injections with either 70 mg or 140 mg per month. The occurrence and alterations of AEs were evaluated. All reported AEs, regardless of their severity, were included. AEs were graded using the common terminology criteria for adverse events (CTCAE). Possible parameters that could influence the occurrence of AEs (sex, episodic or chronic migraine, medication overuse headache, aura and the dosage of erenumab) were analyzed using the Chi-squared test, alpha adjustment was done using the Bonferroni’s correction (6 tests, adjusted alpha = 0.0083). Results The proportion of patients who reported at least one AE were stable over the course of 12 months (after 3mo = 37%, 6mo = 36%, 9mo = 32%, 12mo = 35%). All reported AEs were grade 1 according to CTCAE with one exception (grade 2). Throughout the interval, five AEs were mostly reported: constipation, skin reactions, fatigue, sleep disturbances and nausea/emesis. Discontinuation of erenumab therapy was rarely caused by AEs (5/49). Increasing the dosage from 70 mg to 140 mg per month caused no higher frequency of AEs (Chi-squared test, p = 0.57). Significant more AEs were reported by females and by patients with aura (Chi-squared test, p < 0.001, respectively). Conclusion In general, erenumab is well tolerated up to a treatment interval of 12 months and reported AEs rarely lead to discontinuation of therapy. A higher dosage does not increase the patient reported AEs. Furthermore, no habituation of AEs is observed. Nevertheless, females and patients with aura seem to be more prone to have AEs. Trial registration No registration, retrospective analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Hence, SP potentiates the mechanisms and pathways triggering the translation of proteins and transcription factors involved in the switching (off and on) of the genes responsible for the cancer progression pathways. NK-1R inhibition by specific antagonists may be a novel strategy to control and manage the cancers [23,39]. SP binds to NK-1R and induces the activation of tumour pathways such as proliferation, invasion, angiogenesis, and migration of tumour cells to metastasize/metastasis.…”

Section: Discussionmentioning

confidence: 99%

Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma

Mehboob¹,

Kurdi²,

Baeesa³

et al. 2022

View full text Add to dashboard Cite

Introduction:Neurokinin-1 receptor (NK-1R) induces inflammatory reactions in peripheral tissues but its regulatory effects in target tissues is dependent on receptor signalling. Substance P (SP) has a high affinity for the NK-1R, to which it binds preferentially. We aimed to investigate the expression of NK-1R in World Health Organization (WHO) grade 4 astrocytomas as well as in oral squamous cell carcinoma (OSCC) and urothelial carcinoma, and its association with disease progression. Material and methods: The study included tissue samples from 19 brain astrocytomas, 40 OSCCs and 10 urothelial carcinomas. NK-1R expression was quantitatively assessed in the tumour cells using immunohistochemistry. The relationship between NK-1R expression in astrocytomas and recurrence-free interval has been explored. Results: The results showed that the NK-1R was intensely expressed in patients with WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. However, cases clinically diagnosed as a low-grade cancer showed reduced NK-1R expression. Conclusions: NK-1R is overexpressed in all cases of WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. The ubiquitous presence of SP/NK-1R complex during tumour development and progression suggests a possible therapeutic key strategy to use NK-1R antagonist as an adjuvant therapy in the future.

show abstract

“…In the pathogenesis of migraine there is also dura mater vasodilation. 2,15 Serotonin (5-HT) is considered a pain inhibitory agent and is one of the main neurotransmitters of the pain inhibitory pathway. In persistent pain model mice, 5-HT deficiency was associated with decreased thermal hyperalgesia and mechanical allodynia.…”

Section: Discussionmentioning

confidence: 99%

Role of Alkaloid on Platelet Aggregation and Serotonin in Migraine

Adam¹,

Widjiati²

2022

View full text Add to dashboard Cite

show abstract

Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions

Cited by 33 publications

References 241 publications

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma

Role of Alkaloid on Platelet Aggregation and Serotonin in Migraine

Contact Info

Product

Resources

About